Breathe Well Live Well
|
Cytos hits the self-destruct button as PhIIb asthma study bombs
FierceBiotech The Swiss biotech said that its asthma drug CYT003 flunked its primary as well as secondary endpoints in the critically important study, making it all but impossible to raise more funds for the company. As a result, CEO Christian Itin has hit the self … Cytos Begins Layoff Process, Eyes Liquidation After Phase IIb Failure Cytos considering options to wind down company |
View full post on asthma – Google News
|
Cytos Biotechnology soars on results of asthma-drug study
FierceBiotech After closing out a failed Novartis partnership in January, Cytos Biotechnology has registered some upbeat data from a mid-stage study of its lead drug against allergic asthma. On the news, Zurich-based Cytos' shares jumped 14% as of early this morning … Cytos Rises After Asthma Drug Succeeds in Trial: Zurich Mover The Journal of Allergy and Clinical Immunology Publishes Phase 2a Study … |
View full post on asthma – Google News
|
Cytos Rises After Asthma Drug Succeeds in Trial: Zurich Mover
Bloomberg In a trial among 63 patients in Germany, those treated with the drug, CYT003, had improved control of their asthma after treatment with inhaled corticosteroids stopped, while those who received a placebo saw their disease worsen, Cytos said in a … The Journal of Allergy and Clinical Immunology Publishes Phase 2a Study … |
View full post on asthma – Google News
|
Cytos to Secure up to CHF 37M to Advance Phase II Asthma Immunotherapy
Genetic Engineering News The funds will enable Cytos to conduct a global multicenter Phase IIb trial with its lead product CYT003-QbG10 in patients suffering from allergic asthma as well as to advance the rest of its pipeline. This transaction completes the financial … Cytos revives lead program in $40M financing deal with Amgen, venBio |
View full post on asthma – Google News